Manager TitleAgeSince
President - 14/12/2023
Investor Relations Contact - -
Director TitleAgeSince
Director/Board Member 57 14/12/2023
Director/Board Member - 14/12/2023
Date Insider Type Main position Quantity % Market Cap.
12/14/23 A Issuer sale

Director

127,934 0.0678%
12/14/23 A Issuer sale

Chief Executive Officer

643,595 0.3411%
12/14/23 A Issuer sale

Director

97,934 0.0519%
Change 5-day change 1-year change 3-year change Capi.($)
-0.07%+4.77% - - 43.15B
-0.74%+3.71%+2.55%+23.02% 51.61B
-1.07%+2.82%+465.96%+570.70% 44.89B
+1.47%+9.79%+35.92%+20.21% 42.77B
+1.44%+7.77%+19.38%+84.65% 42.58B
-0.93%-4.33%+16.18%+55.82% 31.82B
+1.32%+7.30%+33.89%+148.53% 17.33B
-0.60%+1.93% - - 16.63B
+0.27%+4.34%+9.44%+30.48% 14.76B
+1.28%+5.41%+82.40%+46.13% 14.09B
Average +0.24%+4.43%+83.21%+122.44% 30.72B
Weighted average by Cap. +0.13%+4.72%+99.35%+141.34%
Logo Seagen Inc.
Seagen Inc. est spécialisé dans le développement et la commercialisation de thérapies à base d'anticorps monoclonaux destinées au traitement du cancer. Le CA par source de revenus se répartit comme suit : - ventes de produits (87%) ; - royalties (8,4%) ; - revenus issus d'accords de collaboration et de licence (4,6%).
Employees
3,256
  1. Stock Market
  2. Stocks
  3. SGEN Stock